RVL Pharmaceuticals (RVLPQ) Price & Analysis

311 Followers

RVLPQ Stock Chart & Stats

<$0.01

>-$0.01(-99.00%)

At close: Jan 03 4:00 PM EST

<$0.01

>-$0.01(-99.00%)

Day’s Range― - ―

52-Week Range― - ―

Previous CloseN/A

Volume2.10K

Average Volume (3M)N/A

Market Cap

$111.00

Enterprise Value$94.65

Total Cash (Recent Filing)$19.16M

Total Debt (Recent Filing)$58.15M

Price to Earnings (P/E)―

Beta228.88

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding111,406,044

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.97

Price to Sales (P/S)2.02

P/FCF Ratio-2.61

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

RVL Pharmaceuticals News

RVL Pharmaceuticals Ordered to Liquidate by Irish High Court

RVL Pharmaceuticals (RVLPQ) has released an update. The High Court of Ireland has ordered the liquidation of RVL...

2y ago

Rvl Pharmaceuticals Plc (RVLP) Q3 Earnings Cheat Sheet

Rvl Pharmaceuticals Plc (RVLP) is scheduled to report 3rd quarter earnings on 11/15/2023. Regarding Q3 estimates, Wall Street...

3y ago

RVLPQ

RVLPQ FAQ

What was RVL Pharmaceuticals’s price range in the past 12 months?

Currently, no data Available

What is RVL Pharmaceuticals’s market cap?

RVL Pharmaceuticals’s market cap is $111.00.

When is RVL Pharmaceuticals’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were RVL Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is RVL Pharmaceuticals overvalued?

According to Wall Street analysts RVL Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does RVL Pharmaceuticals pay dividends?

RVL Pharmaceuticals does not currently pay dividends.

What is RVL Pharmaceuticals’s EPS estimate?

RVL Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does RVL Pharmaceuticals have?

RVL Pharmaceuticals has 111,406,044 shares outstanding.

What happened to RVL Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of RVL Pharmaceuticals?

Currently, no hedge funds are holding shares in RVLPQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

RVL Pharmaceuticals

RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities extend across the United States, Argentina, and Hungary. Its principal commercial offering is Upneeq (RVL-1201), an ophthalmic solution containing oxymetazoline hydrochloride, specifically formulated to address acquired blepharoptosis, or drooping eyelids, in adults. The company, formerly known as Osmotica Pharmaceuticals plc, officially rebranded to RVL Pharmaceuticals plc in January 2022. Its corporate headquarters are situated in Bridgewater, New Jersey.